MHC one–two punch knocks out cancer
Journal of Experimental Medicine · 2026
DOI: 10.1084/jem.20252203 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Amir Ghorbani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases , Bethesda, MD, USA. Hauptthemen laut MEDLINE: Neoplasms, Antigens, Neoplasm, Histocompatibility Antigens Class I, Histocompatibility Antigens Class II. Die Arbeit nennt 19 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
In this issue of JEM, Zhang et al. (https://doi.org/10.1084/jem.20250025) describe complete T cell antigens (CTAs), comprised of class I and class II immunogenic peptides fused in a single polypeptide that greatly increase the effectiveness of cancer immunotherapy, even when the CTA antigens are not expressed in tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases , Bethesda, MD, USA.
ORCID-Profile: Amir Ghorbani, Jonathan W Yewdell
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Ghorbani, A., & Yewdell, J. W. (2026). MHC one–two punch knocks out cancer. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252203
Vancouver
Ghorbani A, Yewdell JW. MHC one–two punch knocks out cancer. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20252203
BibTeX
@article{Ghorbani2026,
author = {Ghorbani, Amir and Yewdell, Jonathan W},
title = {MHC one–two punch knocks out cancer},
journal = {Journal of Experimental Medicine},
year = {2026},
doi = {10.1084/jem.20252203}
}
EUVIMED